Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25888064 | 0.80 | TDP1 (0.36) | KDM4ETDP1TSHR | |
| SCHEMBL25968485 | 0.79 | TDP1 (0.47) | KDM4ELMNATDP1CNR1ADRA1A | |
| SCHEMBL25968487 | 0.79 | TDP1 (0.47) | KDM4ELMNATDP1CNR1ADRA1A | |
| SCHEMBL11004636 | 0.79 | LMNA (0.38) | KDM4ELMNATDP1CNR1ADRA1A | |
| SCHEMBL4606603 | 0.79 | TDP1 (0.47) | KDM4ELMNATDP1CNR1ADRA1A | |
| SCHEMBL19343054 | 0.76 | TSHR (0.44) | KDM4ELMNATDP1CNR1ADRA1A | |
| SCHEMBL1399076 | 0.75 | KDM4E (0.56) | KDM4ELMNATDP1CNR1ADRA1A | |
| SCHEMBL167485 | 0.73 | LMNA (0.39) | KDM4ELMNATDP1CNR1ADRA1A | |
| SCHEMBL11001406 | 0.70 | LMNA (0.44) | KDM4ELMNATDP1CNR1ADRA1A | |
| SCHEMBL9765967 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218598-A1 | Methods Of Treating Fabry Patients Having Renal Impairment | AMICUS THERAPEUTICS, INC. (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218598-A1 | Methods Of Treating Fabry Patients Having Renal Impairment | GAA, GLA, GBA1 | KDM4E 2885/4885LMNA 579/4885TDP1 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.